Free Trial

Chinook Therapeutics (KDNY) News Today

Notice: This company has been marked as potentially delisted and may not be actively trading.
Chinook Elementary
Chinook Therapeutics, Inc. (NASDAQ:KDNY) is Altium Capital Management LP's 5th Largest Position
Altium Capital Management LP reduced its holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 20.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 305,000 shares of the company's stock after
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Consensus Recommendation of "Hold" from Analysts
Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Free Report) have earned an average recommendation of "Hold" from the thirteen research firms that are currently covering the stock, Marketbeat reports. Ten analysts have rated the stock with a hold rating and three have assigned a buy rating
Citigroup Inc. Boosts Holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Citigroup Inc. raised its position in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 89.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 147,810 shares of the company's stock aft
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Sold by C M Bidwell & Associates Ltd.
C M Bidwell & Associates Ltd. lowered its stake in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 86.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,490 shares of the company's stock
CHI Advisors LLC Makes New Investment in Chinook Therapeutics, Inc. (NASDAQ:KDNY)
CHI Advisors LLC acquired a new stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 135,000 shares of the company's stock, valued at approximately $3,125,000.
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Sold by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. decreased its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 27.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,211 shares of the c
Barclays PLC Lowers Stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Barclays PLC cut its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 17.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 83,925 shares of the company's
Q3 2023 Earnings Forecast for Chinook Therapeutics, Inc. Issued By Wedbush (NASDAQ:KDNY)
Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) - Investment analysts at Wedbush upped their Q3 2023 EPS estimates for Chinook Therapeutics in a research report issued to clients and investors on Tuesday, August 8th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.7
Chinook Therapeutics, Inc. (KDNY)
Expert Ratings for Chinook Therapeutics
Chinook Therapeutics (NASDAQ:KDNY) Downgraded by Wells Fargo & Company to Equal Weight
Wells Fargo & Company downgraded shares of Chinook Therapeutics from an "overweight" rating to an "equal weight" rating in a research note on Tuesday.
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Sold by Baillie Gifford & Co.
Baillie Gifford & Co. lowered its stake in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 0.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 486,595 shares of the company's stock
SG Americas Securities LLC Increases Position in Chinook Therapeutics, Inc. (NASDAQ:KDNY)
SG Americas Securities LLC raised its holdings in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 1,818.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 153,882 shares of the company's stock after acqui
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Average Rating of "Hold" from Analysts
Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Free Report) has been assigned an average recommendation of "Hold" from the thirteen brokerages that are covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation and five have assigned a bu
Chinook Therapeutics (NASDAQ: KDNY)
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Position Increased by Hennion & Walsh Asset Management Inc.
Hennion & Walsh Asset Management Inc. lifted its holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 40.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 36,946 shares of the company's stock after buying an additional 10,5
Short Interest in Chinook Therapeutics, Inc. (NASDAQ:KDNY) Drops By 56.4%
Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 1,820,000 shares, a drop of 56.4% from the May 31st total of 4,170,000 shares. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is currently 1.4 days.
Assenagon Asset Management S.A. Purchases 483,220 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Assenagon Asset Management S.A. grew its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 54.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,371,469 s
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Given Average Recommendation of "Hold" by Analysts
Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) has been given an average recommendation of "Hold" by the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy rating
Victory Capital Management Inc. Grows Holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Victory Capital Management Inc. grew its stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 13.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,163,245 shares of the company's stock after acquiring an additional 136,182 shares durin
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Sold by HealthCor Management L.P.
HealthCor Management L.P. lowered its holdings in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 77.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,000 shares of the company's stock after selling
Novartis Stock Screams Value After Chinook Therapeutics Buyout (KDNY)
Following a buyout of Chinook Therapeutics, Novartis slipped less than 1%. This speaks to the growth potential of Chinook and ongoing value of Novartis stock.
Why Are Chinook Therapeutics Shares Trading Higher Today
What 6 Analyst Ratings Have To Say About Chinook Therapeutics
Novartis Buys Chinook: M&A To Drive Future Growth
Chinook Therapeutics (NASDAQ:KDNY) Downgraded to Neutral at Guggenheim
Guggenheim cut shares of Chinook Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday.
Gyon Technologies Capital Management LP Makes New $496,000 Investment in Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Gyon Technologies Capital Management LP acquired a new position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 18,931 shares of
Chinook Shareholder Action Reminder
ExodusPoint Capital Management LP Sells 41,701 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)
ExodusPoint Capital Management LP lowered its position in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 24.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,955 shares of the company's stock after selling
Principal Financial Group Inc. Grows Stock Holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Principal Financial Group Inc. lifted its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 102.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,555 shares of the company's stock after bu
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Acquired by Mirae Asset Global Investments Co. Ltd.
Mirae Asset Global Investments Co. Ltd. grew its position in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 22.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 24,413 shares of the company's stock after acquiring an additional 4
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Given Average Recommendation of "Buy" by Brokerages
Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) has been given an average rating of "Buy" by the eight analysts that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among br
Connor Clark & Lunn Investment Management Ltd. Sells 51,468 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Connor Clark & Lunn Investment Management Ltd. reduced its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 17.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 235,816 shares of t
Swiss National Bank Acquires 5,200 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Swiss National Bank lifted its holdings in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 5.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 98,700 shares of the com
FY2023 EPS Estimates for Chinook Therapeutics, Inc. (NASDAQ:KDNY) Reduced by Analyst
Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) - Research analysts at Bloom Burton decreased their FY2023 earnings per share estimates for shares of Chinook Therapeutics in a research note issued on Monday, May 22nd. Bloom Burton analyst A. Borovina now forecasts that the company will earn
Get Chinook Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter.

Estee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI company (Ad)

A Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.

Discover this unknown NYSE Tech SaaS company

KDNY Media Mentions By Week

KDNY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KDNY
News Sentiment

0.67

0.88

Average
Medical
News Sentiment

KDNY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KDNY Articles
This Week

0

0

KDNY Articles
Average Week

Get Chinook Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:KDNY) was last updated on 6/13/2024 by MarketBeat.com Staff

From Our Partners